Neovacs S.A. (ALNEV) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.144x

Based on the latest financial reports, Neovacs S.A. (ALNEV) has a cash flow conversion efficiency ratio of -0.144x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.60 Million ≈ $-3.04 Million USD) by net assets (€18.03 Million ≈ $21.08 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review financial agility of Neovacs S.A. to assess the company's free cash flow relative to its total liabilities.

Neovacs S.A. - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how Neovacs S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see how much is Neovacs S.A. worth for the company's overall valuation and market capitalisation.

Neovacs S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Neovacs S.A. ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Reliance Global Group Inc NASDAQ:RELIW	-0.121x
Katapult Holdings Equity Warrants Exp 09 June 2026 NASDAQ:KPLTW	-3.039x
Future Enterprises Limited NSE:FEL	-0.192x
Prairie Lithium Limited AU:PL9	-0.077x
US Solar Fund PLC LSE:USFP	-0.007x
Lion Financial Group Limited NASDAQ:LGHLW	-0.504x
Advent Technologies Holdings Inc NASDAQ:ADNWW	-0.015x
Reviva Pharmaceuticals Holdings Inc NASDAQ:RVPHW	-1.229x

Annual Cash Flow Conversion Efficiency for Neovacs S.A. (2007–2025)

The table below shows the annual cash flow conversion efficiency of Neovacs S.A. from 2007 to 2025. View ALNEV share price today for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€18.03 Million ≈ $21.08 Million	€-5.03 Million ≈ $-5.88 Million	-0.279x	-39.98%
2024-12-31	€18.06 Million ≈ $21.12 Million	€-3.60 Million ≈ $-4.21 Million	-0.199x	-356.68%
2023-12-31	€43.82 Million ≈ $51.23 Million	€-1.91 Million ≈ $-2.24 Million	-0.044x	+56.59%
2022-12-31	€44.23 Million ≈ $51.71 Million	€-4.45 Million ≈ $-5.20 Million	-0.101x	+55.44%
2021-12-31	€43.90 Million ≈ $51.32 Million	€-9.91 Million ≈ $-11.58 Million	-0.226x	+56.14%
2020-12-31	€10.98 Million ≈ $12.84 Million	€-5.65 Million ≈ $-6.61 Million	-0.515x	+82.61%
2019-12-31	€2.74 Million ≈ $3.20 Million	€-8.10 Million ≈ $-9.47 Million	-2.958x	+45.82%
2018-12-31	€2.44 Million ≈ $2.85 Million	€-13.31 Million ≈ $-15.56 Million	-5.461x	+67.61%
2017-12-31	€845.75K ≈ $988.77K	€-14.26 Million ≈ $-16.67 Million	-16.857x	-92.46%
2016-12-31	€1.26 Million ≈ $1.47 Million	€-11.00 Million ≈ $-12.86 Million	-8.759x	-591.16%
2015-12-31	€6.07 Million ≈ $7.09 Million	€-7.69 Million ≈ $-8.99 Million	-1.267x	+12.37%
2014-12-31	€5.57 Million ≈ $6.51 Million	€-8.05 Million ≈ $-9.41 Million	-1.446x	+28.13%
2013-12-31	€3.48 Million ≈ $4.07 Million	€-7.00 Million ≈ $-8.18 Million	-2.012x	-15.00%
2012-12-31	€3.62 Million ≈ $4.23 Million	€-6.33 Million ≈ $-7.40 Million	-1.749x	-114.30%
2011-12-31	€10.57 Million ≈ $12.36 Million	€-8.63 Million ≈ $-10.09 Million	-0.816x	+16.59%
2010-12-31	€8.27 Million ≈ $9.67 Million	€-8.10 Million ≈ $-9.47 Million	-0.979x	-104.34%
2009-12-31	€-352.58K ≈ $-412.20K	€-7.95 Million ≈ $-9.29 Million	22.549x	+3373.12%
2008-12-31	€6.51 Million ≈ $7.61 Million	€-4.49 Million ≈ $-5.25 Million	-0.689x	+68.57%
2007-12-31	€1.97 Million ≈ $2.30 Million	€-4.32 Million ≈ $-5.05 Million	-2.192x	--

About Neovacs S.A.

PA:ALNEV France Biotechnology

Market Cap

$33.63

€28.76 EUR

Market Cap Rank

#31979 Global

#601 in France

Share Price

€0.61

Change (1 day)

-10.00%

52-Week Range

€0.00 - €1.89

All Time High

€3.13